AgomAb Therapeutics NV
AGMB evidence brief
What we can confirm
- Market Cap:
- $604.8M
What it means
What to watch
Prepared research question
What matters most for AGMB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AGMB
AgomAb Therapeutics NV (AGMB) is a clinical-stage biopharmaceutical company focused on fibro-inflammation, with lead programs in fibrostenotic Crohn's disease and idiopathic pulmonary fibrosis.
Key risk: Early-stage pipeline
Market Cap
$604.8M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Tracking 4 clinical trials for AgomAb Therapeutics NV.
AgomAb Therapeutics NV (AGMB) is a clinical-stage biopharmaceutical company focused on fibro-inflammation, with lead programs in fibrostenotic Crohn's disease and idiopathic pulmonary fibrosis.
- Agomab is a clinical-stage biopharmaceutical company focused on fibro-inflammation [news · published 2026-10-01].
- Reported positive 48-week open-label extension results from the Phase 2a STENOVA trial of ontunisertib in fibrostenotic Crohn's disease [news · published 2026-10-01].
- Granted U.S. Patent No. 12,577,230 for AGMB-447, an inhaled lung-restricted small molecule inhibitor of ALK5 for idiopathic pulmonary fibrosis [news · published 2026-04-12].
- Management team to participate in upcoming industry and investor conferences including ATS International Conference 2026 [news · published 2026-05-14].
What works
- Positive 48-week Phase 2a OLE data for ontunisertib in fibrostenotic Crohn's disease, indicating sustained disease control [news · published 2026-10-01].
- U.S. patent granted for AGMB-447, providing intellectual property protection for a novel inhaled lung-restricted approach to IPF [news · published 2026-04-12].
- Active clinical pipeline with multiple Phase 1 and Phase 2 trials underway for both lead assets [catalyst].
What to weigh
- Both lead programs are still in early-to-mid-stage clinical development, with no approved products or late-stage pivotal data yet [news · published 2026-10-01].
- The company operates in competitive therapeutic areas (fibrosis, IPF) with established players and multiple ongoing competitor trials [competitor_trial].
- No financial data (cash, revenue, net loss) is provided in the available chunks, making financial runway assessment impossible.
From the filings
Quoted directly from source documents.
Positive 48-week OLE results from Phase 2a STENOVA trial
“Agomab Therapeutics NV (‘Agomab’) a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced positive results of the 48-week OLE portion of the Phase 2a STENOVA trial evaluating”
News · October 1, 2026
U.S. patent granted for AGMB-447
“Agomab Therapeutics NV (NASDAQ:AGMB) is one of the 7 Best Strong Buy European Stocks to Invest In. On March 26, 2026, Agomab Therapeutics NV (NASDAQ:AGMB) announced that the U.S. Patent and Trademark Office granted U.S. Patent No. 12,577,230 covering the composition of matter for AGMB-447.”
News · April 12, 2026
Company focus on fibro-inflammation
“Agomab Therapeutics NV (‘Agomab’) a clinical-stage biopharmaceutical company focused on fibro-inflammation”
News · October 1, 2026
Catalyst timeline
- 2023-08-01 · Phase 2a start for AGMB-129 in fibrostenotic Crohn's disease — A Phase 2a, randomized, placebo-controlled, double-blind study to assess safety, PK, and PD of AGMB-129.
- 2023-12-01 · Phase 1 start for inhaled AGMB-447 in IPF — A Phase I, randomized, double-blind, placebo-controlled, single and multiple ascending dose study in healthy participants and IPF patients.
- 2025-08-06 · Phase 1 start for AGMB-129 in healthy participants — A Phase 1, double-blind, randomized, placebo-controlled, multiple ascending dose study to assess safety, tolerability, and PK of AGMB-129.
- 2026-09-09 · Phase 1 start (open-label) for AGMB-129 — An open-label, two... (incomplete description).
Risks & what to watch (3)›
Key risks
- Early-stage pipeline — Both lead assets are in Phase 1/2a; no approved products or pivotal data yet [news · published 2026-10-01].
- Competitive landscape — Multiple competitor trials in respiratory and fibrotic conditions from Pfizer, Merck, etc. [competitor_trial].
- No financial data available — No cash, revenue, or deficit figures in provided chunks; financial health unknown.
What to watch
- Phase 1 data for inhaled AGMB-447 in IPF (started 2023-12-01) [catalyst].
- Phase 2a STENOVA trial full results and potential Phase 2b initiation for ontunisertib [news · published 2026-10-01].
- Upcoming conference presentations and investor meetings (e.g., ATS 2026) [news · published 2026-05-14].
Sources: Catalysts · Competitor trials · News · Generated October 13, 2026 · How we verify sources →
Run AgomAb Therapeutics NV through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AgomAb Therapeutics NV facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
32
Total value held
$245.0M
| Holder | Shares | Value |
|---|---|---|
| eqt fund management s.a r.l. | 5,141,992 | $53.9M |
| sanofi | 2,783,096 | $29.2M |
| cormorant asset management, lp | 2,465,348 | $25.9M |
| tcg crossover management, llc | 2,053,233 | $21.5M |
| federated hermes, inc. | 1,618,000 | $17.0M |
| casdin capital, llc | 1,550,000 | $16.3M |
| andera partners | 1,538,702 | $16.1M |
| fmr llc | 1,458,677 | $15.3M |
| nantahala capital management, llc | 1,200,000 | $12.9M |
| aberdeen group plc | 707,656 | $7.4M |
Showing top 10 of 32 institutional holders of AgomAb Therapeutics NV. Open the full 13F history after sign-in.
Short Interest
as of May 1, 2026- % of float
- 1.1%
- Days to cover
- 2.1
- Shares short
- 433,265
- Daily short volume (May 12, 2026)
- 71.8%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AGMB short interestFrequently asked questions
What is the AI investment thesis for AgomAb Therapeutics NV?
AgomAb Therapeutics NV (AGMB) is a clinical-stage biopharmaceutical company focused on fibro-inflammation, with lead programs in fibrostenotic Crohn's disease and idiopathic pulmonary fibrosis.
Who is the CEO of AgomAb Therapeutics NV?
Dr. Tim Knotnerus MSc, Ph.D. is the chief executive officer of AgomAb Therapeutics NV (AGMB).
Where is AgomAb Therapeutics NV headquartered?
AgomAb Therapeutics NV (AGMB) is headquartered in Antwerp, Belgium.
What therapeutic areas does AgomAb Therapeutics NV focus on?
AgomAb Therapeutics NV develops therapies across Immunology, Metabolic, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.